This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
WBB Securities Initiates a Buy Rating on enGene Holdings (ENGN)
enGene Holdings received a Buy rating and a $21.50 price target from WBB Securities analyst today.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
In a report released on April 2, Wells Fargo also assigned a Buy rating to the stock with a $25.00 price target.
Based on enGene Holdings’ latest earnings release for the quarter ending January 31, the company reported a quarterly GAAP net loss of $29.75 million. In comparison, last year the company had a GAAP net loss of $24.62 million
Read More on ENGN:
Disclaimer & DisclosureReport an Issue
- enGene initiated with a Buy at WBB Securities
- enGene Therapeutics Rebrands as Company Nears Commercialization
- enGene Rebrands as enGene Therapeutics Ahead of Planned Bladder Cancer Gene Therapy Filing
- enGene Rebrands as enGene Therapeutics Ahead of Potential 2027 Commercial Launch
- enGene announces name change to enGene Therapeutics
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
